期刊
VACCINE
卷 29, 期 8, 页码 1538-1544出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.11.091
关键词
Adjuvant; LT; LTB; LTK63
资金
- National Health and Medical Research Council (Australia)
- CAPES (Brazilian Ministry of Education)
- Pfizer Australia
The heat-labile enterotoxin of Escherichia coli (LT) consists of an enzymatically active A subunit (LTA) and a pentameric B subunit (LTB). LT has been extensively studied as a potent modulator of immune responses but wild-type LT is toxic and therefore unsuitable for clinical use. Approaches pursued to avoid the toxicity associated with the use of the native toxin while retaining its adjuvant properties have included isolation of subunit B (LTB) and construction of non-toxic LT AB complex mutants, such as LTK63 mutant. Here we review the immunomodulatory characteristics of LTB and LTK63 and their potential as mucosal and parenteral vaccine adjuvants. (C) 2010 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据